$Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma$

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma

Abstract Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to ant...

Full description

Bibliographic Details
Main Authors:	Weiping Liu, Ningjing Lin, Xinqin Feng, Yan Xie, Chong You, Xiaohua Zhou, Yuqin Song, Jun Zhu
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-09-01
Series:	Signal Transduction and Targeted Therapy
Online Access:	https://doi.org/10.1038/s41392-023-01600-7

Similar Items

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
by: Yanfei Liu, et al.
Published: (2024-03-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
by: Chen Zhang, et al.
Published: (2023-05-01)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
by: Michael P. Randall, et al.
Published: (2023-09-01)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
by: Anastasia Semenova, et al.
Published: (2023-08-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
by: Selma Addou, et al.
Published: (2021-10-01)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
by: John Timmerman, et al.
Published: (2022-10-01)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
by: Artem Gusak, et al.
Published: (2021-11-01)

Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
by: Esther E. E. Drees, et al.
Published: (2022-07-01)

T026 (0025) A PHASE II STUDY OF SHR-1210, AN ANTI-PD-1 ANTIBODY, IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA
Published: (2018-10-01)

P104 (0004) NIVOLUMAB IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA: EXPERIENCE WITH TEN PATIENTS
Published: (2018-10-01)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: Nesreen Ali, et al.
Published: (2023-08-01)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
by: Peter Borchmann, et al.
Published: (2022-10-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
by: Harsh Shah, et al.
Published: (2022-10-01)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: D. Ermann, et al.
Published: (2022-06-01)

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
by: G. Gregory, et al.
Published: (2022-06-01)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
by: F. Kallel, et al.
Published: (2022-06-01)

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Sonja Genadieva Stavrik, et al.
Published: (2021-10-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
by: Esther Hazane Leroyer, et al.
Published: (2022-11-01)

Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
by: Sabine Mai, et al.
Published: (2013-06-01)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
by: Chiara Rusconi, et al.
Published: (2022-10-01)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
by: Liudmila Fedorova, et al.
Published: (2022-10-01)

P017 (0120) IMMUNOLOGIC BIOMARKERS OF RESPONSE AND RESISTANCE TO BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
by: Ya.K. Mangasarova, et al.
Published: (2022-10-01)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
by: Nathalie Johnson, et al.
Published: (2023-08-01)

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
by: John Timmerman, et al.
Published: (2023-08-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
by: Chiara Rusconi, et al.
Published: (2023-08-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group
by: Stephen Daw, et al.
Published: (2020-02-01)

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
by: Jonathan Fromm, et al.
Published: (2022-10-01)